BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/11/2024 10:19:43 AM | Browse: 246 | Download: 1050
Publication Name World Journal of Clinical Oncology
Manuscript ID 98079
Country China
ISSN 2218-4333 (online)
Open Access Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Retrospective Study
Article Title Programmed cell death 1 inhibitor sintilimab plus S-1 and gemcitabine for liver metastatic pancreatic ductal adenocarcinoma
Manuscript Source Unsolicited Manuscript
All Author List Shi-Qiong Zhou, Peng Wan, Seng Zhang, Yuan Ren, Hong-Tao Li and Qing-Hua Ke
ORCID
Author(s) ORCID Number
Shi-Qiong Zhou http://orcid.org/0009-0000-5619-2978
Peng Wan http://orcid.org/0009-0002-8398-6540
Seng Zhang http://orcid.org/0009-0000-6956-6326
Yuan Ren http://orcid.org/0009-0007-0995-5793
Hong-Tao Li http://orcid.org/0009-0000-2693-4993
Qing-Hua Ke http://orcid.org/0009-0003-3582-3824
Funding Agency and Grant Number
Corresponding Author Qing-Hua Ke, Chief Physician, PhD, Department of Chemoradiotherapy, The First Affiliated Hospital of Yangtze University, No. 40 Jinglong Road, Shashi District, Jingzhou 434000, Hubei Province, China. 3803354759@qq.com
Key Words Immunotherapy; Programmed cell death 1 inhibitor; Sintilimab; Chemotherapy; Metastatic; Pancreatic ductal adenocarcinoma
Core Tip This study aimed to explore the feasibility and effectiveness of combining the programmed cell death 1 inhibitor sintilimab with S-1 and gemcitabine (combination group) vs using S-1 and gemcitabine alone (chemotherapy group) for treating liver metastatic pancreatic adenocarcinoma. The combination of programmed cell death 1 inhibitor sintilimab with S-1 and gemcitabine demonstrated effectiveness and safety for treating liver metastatic pancreatic ductal adenocarcinoma, meriting further investigation.
Publish Date 2024-12-11 10:19
Citation

Zhou SQ, Wan P, Zhang S, Ren Y, Li HT, Ke QH. Programmed cell death 1 inhibitor sintilimab plus S-1 and gemcitabine for liver metastatic pancreatic ductal adenocarcinoma. World J Clin Oncol 2025; 16(2): 98079

URL https://www.wjgnet.com/2218-4333/full/v16/i2/98079.htm
DOI https://dx.doi.org/10.5306/wjco.v16.i2.98079
Full Article (PDF) WJCO-16-98079-with-cover.pdf